Skip to content

Observation on the clinical curative effect of external application of Rebi ointment in treating rheumatoid arthritis (damp-heat syndrome) joint pain

Observation on the clinical curative effect of external application of Rebi ointment in treating rheumatoid arthritis (damp-heat syndrome) joint pain

Status
Recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2100041821
Enrollment
Unknown
Registered
2021-01-06
Start date
2021-01-01
Completion date
Unknown
Last updated
2021-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Sponsors

Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Patients meeting the ACR / EULAR diagnostic criteria for RA in 2010; 2. Patients who meet the diagnostic criteria of traditional Chinese medicine (TCM) syndromes of Bi dampness heat obstruction syndrome; 3. Subjects aged between 18 and 70, regardless of gender; 4. For the subjects whose X-ray staging of the joints of both hands belongs to stage I and II, the joint function classification belongs to grade I, II and III; 5. 2.6 < DAS28 < 5.1; 6. Patients with at least pain or swelling of both wrists; 7. Patients who use hormones, hormone suspects or biological agents need to stop taking drugs for more than 3 months; 8. Subjects who did not use NSAIDs or topical analgesics at least one week before enrollment. 9. The volunteers signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with other rheumatic immune diseases, such as systemic lupus erythematosus, Sjogren's syndrome, severe osteoarthritis, etc; 2. Patients with serious diseases such as cardiovascular, lung, liver, gastrointestinal tract, kidney, hematopoietic system or tumor, or complicated with various acute and chronic infections or other infectious diseases (hepatitis, tuberculosis, etc.); 3. Subjects with local skin damage, infection or injury of the joints; 4. No response to methotrexate and leflunomide; 5. Subjects with contraindications (pulmonary fibrosis, etc.) and allergic history of experimental drugs; 6. History of alcohol abuse, drug abuse or neuropsychiatric disorders (epilepsy, depression, etc.); 7. Pregnant or lactating women have a family planning in the near future; 8. Subjects who are participating in clinical research of other drugs.

Design outcomes

Primary

MeasureTime frame
Curative effect of Chinese medicine disease;TCM syndrome score;DAS28 score;Number of joint swelling;Number of joint tenderness;Morning stiffness;Pain degree VAS score;

Secondary

MeasureTime frame
Patient Outcome Clinical Report PRO Scale Score;Joint function classification;VAS score for the overall condition of the disease assessed by the patient;VAS score for the overall condition of the disease as assessed by the investigator;ACR20 compliance ratio;Grip;Semi-quantitative evaluation of wrist ultrasound;Erythrocyte Sedimentation Rate ;C reactive protein;Rheumatoid factor classification;Anti-cyclic citrullinated peptide antibody;

Countries

China

Contacts

Public ContactWu Yang

Yunnan Provincial Hospital of Traditional Chinese Medicine/The First Affiliated Hospital of Yunnan University of Traditional Chinese Medicine

wy13187705354@126.com+86 13187705354

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026